Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Washington University School of Medicine
With
Notable Labs
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Peripheral blood blasts \> 1%
Peripheral white blood cell count \> 1,000/µl.
Age ≥ 18 years
Anticipated treatment with any of the following regimens (Cohort 0) or:
* Cohort 1: A standard induction protocol with infusional cytarabine
* Cohort 2: Decitabine (either 5-day or 10-day regimens)
* Cohort 3: Azacitidine (either intravenous or subcutaneous administration)
* Cohort 4: Decitabine (either 5-day or 10-day) + venetoclax
* Cohort 5: Azacitidine (either intravenous or subcutaneous administration on 7 day or 5+2+2 schedule) + venetoclax
Patients may receive these therapies as part of other on-going clinical trials or as standard of care treatment.
Patients in Cohort 1 may receive SOC midostaurin or gemtuzumab ozogamicin, provided these start after the Day 2 sample is collected. Patients in Cohort 1 may receive a standard combination of cytarabine/idarubicin, cytarabine/daunorubicin, or Vyxeos, a liposomal formulation of cytarabine and daunorubicin.
ECOG performance status ≤ 3
Ability to understand and willingness to sign an IRB approved written informed consent document.
Currently receiving any other investigational agents.
You may not be if
Pregnant or currently nursing
Prior chemotherapy with hypomethylating agents
Known history of positive HIV serology.
Known positive Hepatitis C serology.
Clareo Health | AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
